

Discovery of Lead Compounds for the Treatment of Progressive Supranuclear Palsy by Controlling 4R Tauopathy

Korea Institute of Science and Technology



NEUROSCIENCE	Lead
Product Type	Chemical Small Molecule
Indication	Progressive Supranuclear Palsy (PSP), Primary Tauopathy
Target	Tau Oligomerization
MoA(Mechanism of Action)	Inhibition of Tau Oligomerization
Competitiveness	Direct suppression of 4R tau oligomerization that is pathologically specific to Progressive Supranuclear Palsy
Development Stage	Lead Generation
Route of Administration	Oral Administration